Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Lipkowitz

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Cancer Gene Therapy|February 29, 2024
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerKei Kudo, Yoshimi Endo Greer, Teruhiko Yoshida, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutationNicholas W Choong, Sascha Dietrich, Tanguy Y Seiwert, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growthDavid J Wisniewski, Donna Voeller, Yonit A Addissie, et al.
Clinical & Experimental Metastasis|August 5, 2025
A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical modelsWei Zhang, Samiur Rahman, Alex M L Wu, et al.
Cell Reports|February 11, 2014
E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammationGuilin Qiao, Haiyan Ying, Yixia Zhao, et al.
Marine Drugs|July 2, 2021
Agelasine Diterpenoids and Cbl-b Inhibitory Ageliferins from the Coralline Demosponge <i>Astrosclera willeyana</i>Wei Jiang, Dongdong Wang, Brice A P Wilson, et al.
Oncogene|November 25, 2025
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibitionDavid J Wisniewski, Donna Voeller, Yonit A Addissie, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancersDavid J Wisniewski, Rachel K Pritz, Jake Munch, et al.
The Oncologist|June 9, 2020
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast CancerMargaret E Gatti-Mays, Fatima H Karzai, Sanaz N Soltani, et al.
Breast Cancer Research and Treatment|December 17, 2017
Analysis of breast cancer in young women in the Department of Defense (DOD) databaseAlexandra S Zimmer, Kangmin Zhu, Patricia S Steeg, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Cancer Gene Therapy|February 29, 2024
Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancerKei Kudo, Yoshimi Endo Greer, Teruhiko Yoshida, et al.
Nature Clinical Practice. Oncology|January 13, 2006
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutationNicholas W Choong, Sascha Dietrich, Tanguy Y Seiwert, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Dual inhibition of EGFR and PI3Kinase signaling in EGFR amplified triple negative breast cancer cells induces apoptosis and reduces tumor growthDavid J Wisniewski, Donna Voeller, Yonit A Addissie, et al.
Clinical & Experimental Metastasis|August 5, 2025
A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical modelsWei Zhang, Samiur Rahman, Alex M L Wu, et al.
Cell Reports|February 11, 2014
E3 ubiquitin ligase Cbl-b suppresses proallergic T cell development and allergic airway inflammationGuilin Qiao, Haiyan Ying, Yixia Zhao, et al.
Marine Drugs|July 2, 2021
Agelasine Diterpenoids and Cbl-b Inhibitory Ageliferins from the Coralline Demosponge <i>Astrosclera willeyana</i>Wei Jiang, Dongdong Wang, Brice A P Wilson, et al.
Oncogene|November 25, 2025
EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibitionDavid J Wisniewski, Donna Voeller, Yonit A Addissie, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Loss of Flotillin-2 enhances trastuzumab emtansine internalization and cytotoxicity by relieving negative regulation of HER2 internalization in HER2-amplified cancersDavid J Wisniewski, Rachel K Pritz, Jake Munch, et al.
The Oncologist|June 9, 2020
A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast CancerMargaret E Gatti-Mays, Fatima H Karzai, Sanaz N Soltani, et al.
Breast Cancer Research and Treatment|December 17, 2017
Analysis of breast cancer in young women in the Department of Defense (DOD) databaseAlexandra S Zimmer, Kangmin Zhu, Patricia S Steeg, et al.
Pageof 11